Brief: Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
01/03/2023 22:07
March 1 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA REPORTS FULL YEAR 2022 FINANCIAL RESULTS,
PROVIDES
CLINICAL DEVELOPMENT UPDATES
* LUMOS PHARMA INC - PRIMARY OUTCOME DATA FOR BOTH ORAGROWTH
TRIALS EXPECTED Q4 2023
* LUMOS PHARMA INC - PATIENT ENROLLMENT COMPLETED IN
ORAGROWTH210
AND ORAGROWTH212 TRIALS
* LUMOS PHARMA INC - ENDED YEAR ON DECEMBER 31, 2022, WITH
CASH,
CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALING $67.4
MILLION
* LUMOS PHARMA INC - CASH ON HAND AS OF DECEMBER 31, 2022 IS
EXPECTED TO SUPPORT OPERATIONS INTO Q3 OF 2024
Source text for Eikon: ID:nGNX60WyT1
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)